McPherson C P, Swenson K K, Jolitz G, Murray C L
Oncology Research, Institute for Research and Education, HealthSystem Minnesota, Minneapolis 55416, USA.
Cancer. 1997 May 15;79(10):1923-32. doi: 10.1002/(sici)1097-0142(19970515)79:10<1923::aid-cncr13>3.0.co;2-x.
The value of mammographic screening in reducing breast carcinoma mortality among women younger than 50 years continues to be controversial. Previous randomized clinical trials have not been definitive because of inadequate sample sizes, prolonged screening intervals, questionable randomization, and/or cross-contamination between intervention groups. This study uses a historical prospective cohort design to examine differences in prognostic factors at the time of breast carcinoma diagnosis and differences in overall survival among patients ages 40-49 years, according to the method of breast carcinoma detection.
Women (n = 971) ages 40-49 years diagnosed with invasive breast carcinoma between 1986 and 1992 were identified by TUMORS (The Upper Midwest Oncology Registry Services). Measures of tumor size, lymph node status, and overall survival were compared with breast carcinoma patients whose tumors were detected by breast self-exam (BSE), clinical breast exam (CBE), patient incidental finding (PI), or mammography.
Mean tumor size among women in the mammography group was smaller than that among women in the BSE, CBE, and PI groups (P < 0.002). Tumors detected by mammography were significantly more likely to be localized than those detected by other methods (P < 0.0001). Patients whose tumors were detected by mammography had significantly better survival than patients in the other detection method groups, especially among those with smaller tumors (P < 0.0001). This difference persisted even after adjustment for lead time bias.
Women ages 40-49 years whose invasive breast carcinoma is detected by mammography have significantly smaller tumors, more localized disease, and may have a lower risk of mortality than women whose tumors are detected by other methods.
乳腺钼靶筛查在降低50岁以下女性乳腺癌死亡率方面的价值仍存在争议。以往的随机临床试验由于样本量不足、筛查间隔延长、随机化存在问题和/或干预组之间的交叉污染而未得出明确结论。本研究采用历史性前瞻性队列设计,根据乳腺癌检测方法,研究40 - 49岁患者在乳腺癌诊断时的预后因素差异以及总生存率差异。
通过上中西部肿瘤登记服务(TUMORS)确定了1986年至1992年间诊断为浸润性乳腺癌的40 - 49岁女性(n = 971)。将肿瘤大小、淋巴结状态和总生存率的测量结果与通过乳房自我检查(BSE)、临床乳房检查(CBE)、患者偶然发现(PI)或乳腺钼靶检查发现肿瘤的乳腺癌患者进行比较。
乳腺钼靶检查组女性的平均肿瘤大小小于BSE、CBE和PI组女性(P < 0.002)。与通过其他方法检测到的肿瘤相比,通过乳腺钼靶检查检测到的肿瘤更有可能局限(P < 0.0001)。通过乳腺钼靶检查发现肿瘤的患者的生存率明显高于其他检测方法组的患者,尤其是肿瘤较小的患者(P < 0.0001)。即使在调整了领先时间偏倚后,这种差异仍然存在。
与通过其他方法发现肿瘤的女性相比,通过乳腺钼靶检查发现浸润性乳腺癌的40 - 49岁女性的肿瘤明显更小,疾病更局限,并且可能具有更低的死亡风险。